Content about Coagulopathy

November 28, 2012
Novo Nordisk app designed to help hemophilia patients, families

Novo Nordisk has launched a mobile app for hemophilia patients, the drug maker said.

PRINCETON, N.J. — Novo Nordisk has launched a mobile app for hemophilia patients, the drug maker said.

HemaGo — available for iPhone, iPad and Android devices — is designed to track hemophilia treatment, bleeding episodes and life events, helping people with the condition and their caregivers monitor the details of treatment, including medications, dosing, bleeding information and the disease's effects on life events.

July 11, 2012
BioRx receives distribution rights to bleeding disorder drug

Days after its acquisition of Coagulife, specialty pharmacy provider BioRx has received limited distribution rights to a treatment for a bleeding disorder described as one of the rarest in the world.

CINCINNATI — Days after its acquisition of Coagulife, specialty pharmacy provider BioRx has received limited distribution rights to a treatment for a bleeding disorder described as one of the rarest in the world.

The company, which specializes in treating bleeding disorders, said Wednesday that it had received the rights for Corifact (factor XIII concentrate [human]), a treatment made by CSL Behring for congenital Factor XIII deficiency. The drug received approval from the Food and Drug Administration in February 2011.

July 9, 2012
BioRx acquires Minn. bleeding-disorder pharmacy

Specialty pharmacy provider BioRx has acquired another specialty pharmacy provider based in Minnesota, BioRx said Monday.

CINCINNATI — Specialty pharmacy provider BioRx has acquired another specialty pharmacy provider based in Minnesota, BioRx said Monday.

BioRx, based in Cincinnati and specializing in such bleeding disorders as hemophilia, announced the purchase of Savage, Minn.-based Coagulife, which provides similar services.

May 29, 2012
BioPlus promotes Shelley Moore to lead bleeding disorders program

BioPlus Specialty Pharmacy has appointed a new person to head its bleeding disorders program, the company said Tuesday.

ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy has appointed a new person to head its bleeding disorders program, the company said Tuesday.

BioPlus announced the promotion of Shelley Moore to the position of national director of hemophilia. Moore already has served as head of the company's bleeding disorders program for Tennessee and has six years' nursing experience and a career specialty in bleeding disorders.

March 21, 2011
MedPro Rx announces Education Is Power scholarship program

Patients with bleeding disorders could be eligible for a scholarship from a specialty pharmacy provider that specializes in treating them.

RALEIGH, N.C. — Patients with bleeding disorders could be eligible for a scholarship from a specialty pharmacy provider that specializes in treating them.

MedPro Rx announced Sunday that patients with such disorders as hemophilia and von Willebrand disease attending college and active in their communities could be eligible for its Education Is Power scholarship program.

February 24, 2011
Novo Nordisk develops treatment for rarest bleeding disorder, seeks FDA approval

Novo Nordisk has filed for approval of a treatment for a rare genetic bleeding disorder, the Danish drug maker said Wednesday.

PRINCETON, N.J. — Novo Nordisk has filed for approval of a treatment for a rare genetic bleeding disorder, the Danish drug maker said Wednesday.

The company submitted to the Food and Drug Administration its application for recombinant factor XIII compound, for congenital factor XIII deficiency. Current treatments for FXIII deficiency use products derived from human blood plasma, which carries the risk of contamination.

February 18, 2011
FDA OKs Corifact

The Food and Drug Administration has approved a treatment for a rare bleeding disorder.

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for a rare bleeding disorder.

The FDA announced the approval of Corifact, used to prevent bleeding in people with the genetic disorder congenital Factor XIII deficiency, which affects 1-in-3 million to 5 million people in the United States.

The drug is manufactured by Marburg, Germany-based CSL Behring.

August 2, 2010
Octapharma gets orphan drug status for Wilate

The Food and Drug Administration has given orphan drug designation to a treatment for an...

June 27, 2010
Bayer launches mobile app for hemophilia patients

Bayer HealthCare Pharmaceuticals has launched a free mobile application for patients with hemophilia, the drug...

May 12, 2010
Octapharma launches bleeding disorder treatment

A drug for treating the bleeding disorder von Willebrand disease has become available, manufacturer Octapharma...

January 17, 2010
MedPro Rx offering scholarships to students with bleeding disorders

Prospective college students living with bleeding disorders have a chance to receive a scholarship from...